California Code of Regulations
Title 22 - Social Security
Division 9 - Prehospital Emergency Medical Services
Chapter 4 - Emergency Medical Technician-Paramedic
Article 2 - General Provisions
Section 100147 - Paramedic Trial Studies
Current through Register 2024 Notice Reg. No. 38, September 20, 2024
A paramedic may perform any prehospital emergency medical care treatment procedures(s) or administer any medication(s) on a trial basis when approved by the medical director of the LEMSA and the Director of the Authority.
(a) The medical director of the LEMSA shall review a trial study plan, which at a minimum shall include the following:
(b) The medical director of the LEMSA shall appoint a local medical advisory committee to assist with the evaluation and approval of trial studies. The membership of the committee shall be determined by the medical director of the LEMSA, but shall include individuals with knowledge and experience in research and the effect of the proposed study on the EMS system.
(c) The medical director of the LEMSA shall submit the proposed study and send a copy of the proposed trial study plan at least forty-five (45) days prior to the proposed initiation of the study to the Director of the Authority for approval in accordance with the provisions of section 1797.172 of the Health & Safety Code. The Authority shall inform the Commission on EMS (Commission) of studies being initiated.
(d) The Authority shall notify, within fourteen (14) days of receiving the request, the medical director of the LEMSA submitting its request for approval of a trial study that the request has been received, and shall specify what information, if any, is missing.
(e) The Director of the Authority shall render the decision to approve or disapprove the trial study within forty-five (45) days of receipt of all materials specified in subsections (a) and (b) of this section.
(f) The medical director of the LEMSA within eighteen (18) months of initiation of the procedure(s) or medication(s), shall submit a written report to the Commission which includes at a minimum the progress of the study, number of patients studied, beneficial effects, adverse reactions or complications, appropriate statistical evaluation, and general conclusion.
(g) The Commission shall review the above report within two (2) meetings and advise the Authority to do one of the following:
(h) If option (g)(2) is selected, the Commission may advise continuation of the study as structured or alteration of the study to increase the validity of the results.
(i) At the end of the additional eighteen (18) month period, a final report shall be submitted to the Commission with the same format as described in (f) above.
(j) The Commission shall review the final report and advise the Authority to do one of the following:
(k) The Authority may require the trial study(ies) to cease after thirty-six (36) months.
1.
Renumbering and amendment of former Section 100147 to Section
100151, and renumbering and
amendment of Section
100143 to Section 100147 filed
7-10-89; operative 8-9-89 (Register 89, No. 29). For prior history, see
Register 84, No. 20.
2. Renumbering of former section 100147 to
section 100148 and renumbering of former
section 100146 to section 100147,
including amendment of section, filed 3-15-99; operative 4-14-99 (Register 99,
No. 12).
3. Amendment of subsections (a) and (c)(3) filed 9-10-2004;
operative 10-10-2004 (Register 2004, No. 37).
4. Renumbering of
former section 100147 to section
100148 and renumbering and
amendment of former section
100146 to section 100147 filed
2-11-2013; operative 4-1-2013 (Register 2013, No.
7).
Note: Authority cited: Sections 1797.107 and 1797.172, Health and Safety Code. Reference: Sections 1797.3, 1797.172 and 1797.221, Health and Safety Code.
The amended version of this section by Register 2024, No. 38, effective 1/1/2025 is not yet available.